Vitae Pharmaceuticals (VTAE) Misses Q3 EPS by 12c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Vitae Pharmaceuticals (VTAE) Misses Q3 EPS by 12c

Vitae Pharmaceuticals Reports Third Quarter 2015 Operating and Financial Results

November 5, 2015 4:06 PM EST

Announces psoriasis as lead indication for VTP-43742

Conference call scheduled for 4:30 p.m. EST today

FORT WASHINGTON, Pa., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical-stage biotechnology company developing a robust and growing portfolio generated by its proprietary structure-based drug discovery platform, today reported its operating and financial results for the third quarter ended September 30, 2015.

Jeff Hatfield, President and Chief Executive Officer of Vitae, commented, "During the third quarter of 2015, Vitae continued to make meaningful progress with our lead assets, generating positive... More